×
About 4,420 results

ALLMedicine™ Neuromyelitis Optica Center

Research & Reviews  1,625 results

Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple ...
https://doi.org/10.1186/s12883-022-02698-y 10.1016/j.autrev.2013.10.003 10.1001/jamaneurol.2014.2633 10.1007/s10072-021-05427-4 10.1016/j.radcr.2021.09.033 10.7759/cureus.17961 10.1212/WNL.0000000000001729 10.1177/1352458517703803 10.1016/j.msard.2021.103394 10.1212/WNL.0b013e31825fdead 10.1016/j.msard.2016.11.009
BMC Neurology; Lohmann L, Glaser F et. al.

May 19th, 2022 - Since the beginning of the COVID-19 pandemic and development of new vaccines, the issue of post-vaccination exacerbation or manifestation of demyelinating central nervous system (CNS) disorders has gained increasing attention. We present a case of...

Neuro-inflammatory disease following SARS-CoV-2 infection in children.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106400
The Journal of Pediatrics; Aubart M, Roux CJ et. al.

May 17th, 2022 - To describe neurologic, radiologic and laboratory features in children with central nervous system (CNS) inflammatory disease complicating SARS-CoV-2 infection. We focused on CNS inflammatory diseases in children referred from 12 hospitals in the ...

Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotei...
https://doi.org/10.1016/j.jocn.2022.05.002
Journal of Clinical Neuroscience : Official Journal of Th... Duan Z, Feng J

May 16th, 2022 - The neutrophil-to-lymphocyte ratio (NLR) is a biomarker for evaluating disease activity in systemic autoimmune diseases. However, few studies have discussed NLR changes in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Th...

Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder trea...
https://doi.org/10.1016/j.msard.2022.103772
Multiple Sclerosis and Related Disorders; Yamamura T, Araki M et. al.

May 11th, 2022 - Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.|2022|Yamamura T,Araki M,Fujihara K,Okuno T,Misu T,|

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
https://clinicaltrials.gov/ct2/show/NCT01623076

May 11th, 2022 - This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to deci...

see more →

Guidelines  1 results

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515040
Neurology Wingerchuk DM, Banwell B et. al.

Jun 21st, 2015 - Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord i...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  25 results

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
https://clinicaltrials.gov/ct2/show/NCT01623076

May 11th, 2022 - This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to deci...

Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
https://clinicaltrials.gov/ct2/show/NCT05154734

May 10th, 2022 - The investigators primarily aim to observe the time to first relapse from initiation of belimumab treatment. The secondary outcomes are to determine: The safety profile of belimumab in participants with NMO and whether belimumab improves Expanded ...

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
https://clinicaltrials.gov/ct2/show/NCT04614454

Apr 15th, 2022 - Neuromyelitis optica spectrum disorder (NMOSD) is a chronic relapsing autoimmune disease of the central nervous system (CNS) that preferentially targets the optic nerves and spinal cord, leading to paralysis, blindness and death. NMOSD is a rare d...

In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO
https://clinicaltrials.gov/ct2/show/NCT04629274

Mar 31st, 2022 - This is a fundamental, prospective, multi-centres, interventional non-comparative study without the administration of a study product to patients. The objective is to test in vitro the binding of different Imotopes® to class II HLA antigens on per...

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
https://clinicaltrials.gov/ct2/show/NCT02028884

Feb 17th, 2022 - The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NM...

see more →

News  108 results

Does MS Drug Dosing Regimen Need Revising?
https://www.medscape.com/viewarticle/970351

Mar 15th, 2022 - Among patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) receiving ocrelizumab or rituximab, B cell depletion appears to last well past the 6-month dosing regimen typically used with these drugs. The results, ...

EMA Panel Backs Uplizna for Neuromyelitis Optica
https://www.medscape.com/viewarticle/962984

Nov 15th, 2021 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the immunosuppressant inebilizumab (Uplizna, Horizon Therapeutics) for adults with neuromyelitis optica spectrum disorder ...

Which Agent Best for Neuromyelitis Optica?
https://www.medscape.com/viewarticle/961634

Oct 26th, 2021 - A new indirect comparison of the three new FDA-approved treatment options for adults with aquaporin4+ (AQP4+) neuromyelitis optica spectrum disorder (NMOSD), has suggested that eculizumab is far more effective than the other two agents in preventi...

Progressive Disability in MS Explained?
https://www.medscape.com/viewarticle/956124

Aug 6th, 2021 - Differences in lesion evolution may help neurologists distinguish between multiple sclerosis (MS) and other demyelinating disorders in new findings that may help explain differences in disease course, particularly progressive disability in MS. Res...

Common MS Treatment Wears Off More Quickly in Black Patients
https://www.medscape.com/viewarticle/949488

Apr 17th, 2021 - Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS treatment compared to their White peers, new research suggests. In a study of almost 200 patients, Black participant...

see more →

Patient Education  6 results see all →